Purpose: Xerostomia, sialoadenitis, taste dysfunction and nausea are well known toxicities following high dose radioactive iodine (RAI) treatment for well-differentiated thyroid cancer. This prospective study sought to determine the incidence rates for RAI adverse effects and to determine, whether the radioprotector, amifostine could decrease the duration of the adverse effects in single treatm...

BACKGROUND We examined the effects of psychological and behavioral intervention on health-related quality of life and mental health among patients suffering from differentiated thyroid cancer (DTC) treated with postoperative radioactive iodine-131 (RAI). METHODS Sixty patients with DTC, undergoing RAI, were randomly assigned to receive either conventional nursing (n=30) or a 1-year psychologi...

OBJECTIVE To describe the association of the rare and serious complication of liver toxicity in previously healthy Grave's disease (GD) patients after the treatment with radioactive iodine (131)I (RAI). CASE PRESENTATION We report the clinical, laboratory and pathologic findings of 2 cases of severe liver toxicity associated with the treatment with RAI in previously healthy patients with GD. ...

The Rai staging system is widely used and is easy to apply in clinical practice. The system introduced by Binet et al offers an advantage that it consists only of three stages and, therefore, is more practical for initiation of controlled therapeutic trials than the five-stage Rai system. However, when we take into consideration the survival curves, it is important to note that the Rai system h...

Background: Papillary Microcarcinoma (PMC) of thyroid is a rare type of differentiated thyroid cancer (DTC), which according to the World Health Organization measures 1.0 cm or less. The gold standard of treatment of PMC is still controversy. Our aim was to contribute in resolving the debate on the therapeutic choices of the surgical and adjuvant I-131 (RAI) treatment in PMC. Methods: From 2000...

BACKGROUND The purpose of this study was to demonstrate a role for observation of patients with differentiated thyroid cancer (DTC) with persistent, nonlocalizable disease. METHODS Our study was conducted on outpatients seen at our institution from 1999 to 2009 having total thyroidectomy, radioactive iodine (RAI) ablation, measurable serum thyroglobulin (Tg), and no evidence of disease on who...

Radioactive iodine (RAI) is used effectively in the treatment of hyperthyroidism and thyroid cancer, but it is contraindicated during pregnancy. RAI treatment during pregnancy can lead to fetal hypothyroidism, mental retardation and increased malignancy risk in the infant. Pregnancy tests must be performed before treatment in all women of reproductive age. However, at times, RAI is being used b...

Differentiated thyroid cancer (DTC) is the most frequent endocrine tumor with a good prognosis after primary treatment in cases. By contrast, 30‑40% of patients metastatic DTC are unresponsive to 131I radioactive iodide (RAI) due dedifferentiation. Currently, underlying molecular mechanisms dedifferentiation remain elusive and predictive biomarkers lacking. Therefore, present study a...

Objectives: Despite strong evidence regarding the impact of radioactive iodine (RAI) on hematopoietic, genitourinary, and gastrointestinal systems, its role in cardiovascular system needs to be clarified. We hypothesized that presence a presystolic wave could predictive for dysfunction subjects receiving RAI. Thus, we investigated differentiated thyroid cancer (DTC) patients with without RAI th...